TY - JOUR T1 - Proton pump inhibitors use and risk of preeclampsia JF - medRxiv DO - 10.1101/2021.09.15.21263602 SP - 2021.09.15.21263602 AU - Salman Hussain AU - Ambrish Singh AU - Benny Antony AU - Jitka Klugarová AU - Miloslav Klugar Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/20/2021.09.15.21263602.abstract N2 - Preeclampsia is one of the common complications of pregnancy and is characterized by high blood pressure. Proton pump inhibitors (PPIs) are commonly used for the management of gastroesophageal reflux disease among pregnant women. Recently, multiple epidemiological studies suggested the association between PPIs use and the risk of preeclampsia. This study aims to review the evidence and meta-analyse the pooled risk of preeclampsia in PPI users from epidemiological studies. Databases-MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, and CINAHL (EBSCO) as well as sources of grey literature, ProQuest Dissertations & Theses Global, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform will be searched to identify the epidemiological studies assessing the association between PPIs use and the risk of preeclampsia. Study selection, data extraction, and quality assessment will be performed by two independent authors. The risk of bias among included studies will be evaluated by using the Newcastle-Ottawa scale. The pooled effect of PPIs use on the risk of preeclampsia in pregnant women is the primary outcome of interest. Meta-analysis will be performed using Review Manager version 5.4.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSalman Hussain was supported from Operational Programme Research, Development and Education Project, Postdoc2MUNI(No.CZ.02.2.69/0.0/0.0/18/053/0016952); Miloslav Klugar was supported by the INTER-EXCELLENCE grant number LTC20031 Towards an International Network for Evidence based Research in Clinical Health Research in the Czech Republic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be provided in the supplementary files. ER -